Search Results 461-470 of 18364 for alopecia

1. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia. Participating Mayo Clinic ...

2. A Study Of The Pan-KRAS Inhibitor LY4066434 In Participants With KRAS Mutant Solid Tumors - Mayo Clinic

   ... alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy * Have significant cardiovascular disease defined ...

3. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. Radiation therapy administered within 2 weeks ...

4. Leukoplakia - Doctors and departments - Mayo Clinic

   Lichen sclerosus, Lichen planus, Skin wrinkles, Vulvar disorder, Acne, Alopecia areata, Melasma, Age spots, UV skin damage, Rosacea, Canker sores, Actinic ...

5. Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma - Mayo Clinic

   ... alopecia, or peripheral neuropathy up to grade 2 - Any major surgery =< 4 weeks prior to registration - Any serious and/or unstable pre-existing medical ...

6. Alendronate and cholecalciferol (oral route) - Side effects & dosage - Mayo Clinic

   Alendronate and cholecalciferol combination is used to treat osteoporosis (thinning of the bone) in women after menopause. This medicine may also be used to ...

7. DAREON™-9: A Study To Test How Well Different Doses Of BI 764532 Are Tolerated By People With Small Cell Lung Cancer When Taken Together With A Single Agent Chemotherapy - Mayo Clinic

   Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia ...

8. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b - Mayo Clinic

   Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 except alopecia, stable immune-related toxicity such as ...

9. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

10. Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia - Mayo Clinic

    ... alopecia * Platelet count >= 20,000/mm\^3 (obtained =< 14 days prior to pre-registration) * Total bilirubin =< 1.5 x upper limit of normal (ULN) (=< 3 x ULN ...